SCHEMBL13941636

SCHEMBL13941636

C=C(N)N/N=C(\C)c1ccc2[nH]c(C(=O)Nc3ccc4cc[nH]c4c3)cc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.49
▸ ESR1 P03372 5/20 0.48
▸ PLD2 O14939 1/20 0.46
▸ PLD1 Q13393 1/20 0.46
▸ EGFR P00533 2/20 0.43
▸ PIK3CA P42336 2/20 0.43
▸ NHERF1 O14745 1/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ TP53 P04637 2/20 0.41
▸ MAPT P10636 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ MAOA P21397 1/20 0.40
▸ MAOB P27338 1/20 0.40
▸ CFTR P13569 1/20 0.39
▸ GABRA1 P14867 1/20 0.39
▸ GABRB1 P18505 1/20 0.39
▸ GABRA5 P31644 1/20 0.39
▸ GABRA3 P34903 1/20 0.39
▸ GABRA2 P47869 1/20 0.39
▸ GABRB2 P47870 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13941632 0.94 NPC1 (0.55) NPC1PLD2PLD1EGFRPIK3CA
SCHEMBL13941473 0.91 NPC1 (0.49) NPC1ESR1PLD2PLD1EGFR
SCHEMBL13941634 0.86 EGFR (0.56) NPC1PLD2PLD1EGFRPIK3CA
SCHEMBL13941711 0.86 EGFR (0.50) NPC1PLD2PLD1EGFRPIK3CA
SCHEMBL13941719 0.86 ESR1 (0.44) NPC1ESR1PLD2PLD1EGFR
SCHEMBL16138542 0.86 ESR1 (0.44) NPC1ESR1PLD2PLD1EGFR
SCHEMBL13941706 0.86 MAOA (0.54) NPC1PLD2PLD1EGFRPIK3CA
SCHEMBL13941709 0.85 EGFR (0.49) NPC1PLD2PLD1EGFRPIK3CA
SCHEMBL13941722 0.85 POLB (0.49) NPC1PLD2PLD1EGFRPIK3CA
SCHEMBL13941469 0.84 NPC1 (0.55) NPC1PLD2PLD1EGFRPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765802-B2 Kinase inhibitors, compositions thereof, and methods of use therewith PROVID PHARMACEUTICALS, INC. (US) 2014-07-01 — — US disclosed
US-20090018141-A1 KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH PROVID PHARMACEUTICALS, INC. 2009-01-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018141-A1 KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH CHEK2, ATM, CHEK1 NPC1 3750/4885ESR1 3573/4885PLD2 3431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback